Systemic Sclerosis: Emerging Biologics Ahead Systemic Sclerosis, also known as Scleroderma, is a chronic autoimmune disease marked by abnormal connective tissue growth. This condition results in skin thickening, fibrosis of internal organs, and damage to blood vessels. It can severely affect the skin, lungs, heart, kidneys, and digestive tract. The disease manifests with a complex and diverse clinical profile, and although the exact cause is not fully understood, both genetic and environmental factors contribute to its development. There remains a significant unmet need for more effective treatments, as current therapies mainly aim to control symptoms and slow disease progression. Curious about the numbers? Dive into the data with our infographic!: Click Here Epidemiological Segmentation of Systemic Sclerosis The epidemiology of Systemic Sclerosis in the 7MM from 2020 to 2034 is segmented as follows: Total diagnosed prevalent cases Gender-specific diagnosed cases Age-specific diagnosed cases Type-specific diagnosed cases Severity-specific diagnosed cases Cases associated with complications Systemic Sclerosis Epidemiology In 2023, the prevalence of Systemic Sclerosis varied across the 7MM countries. The United States had the highest number of diagnosed prevalent cases, estimated at approximately 102,100. Among the EU4 countries and the UK, Italy reported the highest diagnosed case numbers, followed by Germany, with Spain having the lowest. Limited systemic sclerosis was more common than diffuse systemic sclerosis and systemic sclerosis sine scleroderma. In the US, nearly 62% of diagnosed cases in 2023 were in the 40–69 age group. Track the trends in DCM & more—explore the data visually!: Click Here Systemic Sclerosis Market The total market size for Systemic Sclerosis in the 7MM was around USD 1.85 billion in 2023. Market Drivers New therapies such as LUMICEF (BRODALUMAB), BENLYSTA, SAPHNELO, and UPLIZNA provide targeted treatment options that have the potential to improve patient outcomes. Increasing disease awareness and improvements in early diagnostic techniques support earlier diagnosis and better disease management, driving market growth. Market Barriers The heterogeneity of Systemic Sclerosis and its varied clinical manifestations make the development and assessment of treatments challenging, leading to unpredictable patient responses. High treatment costs and limited availability of novel therapies, especially in regions with less developed healthcare infrastructure, pose significant obstacles to market expansion. Emerging Therapies for Systemic Sclerosis LUMICEF (BRODALUMAB) BENLYSTA SAPHNELO UPLIZNA VIXARELIMAB AVENCIGUAT DERSIMELAGON EFZOFITIMOD FIPAXALPARANT VASCULAN Others Key Industry Players Kyowa Kirin GSK AstraZeneca Amgen (Horizon Therapeutics) Mitsubishi Tanabe Pharma Roche (Genentech) Kiniksa Pharmaceuticals Boehringer Ingelheim aTyr Pharma Kyorin Pharmaceutical Cumberland Pharmaceuticals Others https://www.delveinsight.com/infographics/systemic-sclerosis-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr